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Abstract
Background: Trials of intermittent preventive treatment against malaria in infants (IPTi) using sulphadoxine-pyrimethamine
(SP) have shown a positive, albeit variable, protective efficacy against clinical malaria episodes. The impact of IPTi in
different epidemiological settings and over time is unknown and predictions are hampered by the lack of knowledge about
how IPTi works. We investigated mechanisms proposed for the action of IPTi and made predictions of the likely impact on
morbidity and mortality.
Methods/Principal Findings: We used a comprehensive, individual-based, stochastic model of malaria epidemiology to
simulate recently published trials of IPTi using SP with site-specific characteristics as inputs. This baseline model was then
modified to represent hypotheses concerning the duration of action of SP, the temporal pattern of fevers caused by
individual infections, potential benefits of avoiding fevers on immunity and the effect of sub-therapeutic levels of SP on
parasite dynamics. The baseline model reproduced the pattern of results reasonably well. None of the models based on
alternative hypotheses improved the fit between the model predictions and observed data. Predictions suggest that IPTi
would have a beneficial effect across a range of transmission intensities. IPTi was predicted to avert a greater number of
episodes where IPTi coverage was higher, the health system treatment coverage lower, and for drugs which were more
efficacious and had longer prophylactic periods. The predicted cumulative benefits were proportionately slightly greater for
severe malaria episodes and malaria-attributable mortality than for acute episodes in the settings modelled. Modest
increased susceptibility was predicted between doses and following the last dose, but these were outweighed by the
cumulative benefits. The impact on transmission intensity was negligible.
Conclusions: The pattern of trial results can be accounted for by differences between the trial sites together with known
features of malaria epidemiology and the action of SP. Predictions suggest that IPTi would have a beneficial impact across a
variety of epidemiological settings.
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Introduction
Intermittent preventive treatment in infants (IPTi) involves
giving antimalarial drugs at scheduled times during the first year of
life, irrespective of whether the infants have malaria infections [1].
The limited number of doses is intended to retain the benefits of
weekly or fortnightly chemoprophylaxis whilst avoiding the
disadvantages: thus reducing malaria morbidity and mortality
while minimising difficulties in sustainability, accelerating drug
resistance or impairing the development of natural immunity.
IPTi trials to date have shown a strong, albeit variable, protective
efficacy against clinical episodes of malaria in the first year of life [2].
How the impact of IPTi varies over time and in different
epidemiological settings is unknown. Prediction is hampered by
the lack of knowledge of both how IPTi works and the extent to
which different trial characteristics may account for the variability in
the observed estimates. Trial characteristics which have been
highlighted are levels of drug resistance, transmission intensity,
seasonality, IPTi schedule, and other interventions for malaria
control (such as insecticide-treated nets (ITN) and treatment
coverage) [2–4]. We use these characteristics as inputs to a stochastic
simulation model of malaria epidemiology. We then modify this
model to represent hypotheses that have been proposed for the
mechanism of IPTi to investigate which of these hypotheses are
consistent, and which cannot be reconciled, with the observed trial
results. The hypotheses, defined in the Methods section, concern the
duration of action of SP, the temporal pattern of fevers caused by
individual infections, the potential benefits for acquired immunity of
avoiding episodes and the effect of sub-therapeutic levels of SP on
parasite dynamics. We then use the model which best fits our criteria
to make predictions of the impact of IPTi in different epidemiolog-
ical settings and with varying drug characteristics.
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Methods
Model 1 (Baseline model): Model of malaria
epidemiology taking into account between-trial
differences
We combine a published model of malaria epidemiology [5]
with an added component for the action of SP [6] and input the
different trial characteristics such as transmission intensity and
treatment coverage. This allows us to see if the between-trial
differences in combination with this model can account for the
heterogeneity in observed efficacy estimates.
Model for malaria epidemiology. The model is individual-
based and stochastic, and is fully described elsewhere [5]. Briefly,
there is a simulated population of individuals who are updated at
five-day timesteps via model components representing new
infections, parasite densities, acquired immunity, morbidity,
mortality and infectivity to mosquitoes (Figure 1). The course of
parasite densities over an infection are described by averaged
empirical data (described in [7]). Immunity to asexual parasites is
derived from a combination of cumulative exposure to both
inoculations and parasite densities, and maternal immunity [7].
The inclusion of acquired immunity allows us to model potential
effects of IPTi on immunity through loss of exposure. The
probability of a clinical attack of malaria depends on the current
parasite density and a pyrogenic threshold (described in [8]). The
pyrogenic threshold responds dynamically to recent parasite load,
increasing or saturating through exposure to parasites and decaying
with time, and thus is individual- and time- specific. Severe malaria
can arise in two ways, either as a result of overwhelming parasite
densities or through uncomplicated malaria with concurrent non-
malaria co-morbidity [9]. Mortality can be either direct (following
severe malaria) or indirect (uncomplicated malaria in conjunction
with co-morbidity, or during the neonatal period as a result of
maternal infection) [9]. The parameter values for this model were
estimated by fitting to data from a total of 61 malaria field studies of
various different aspects of malaria epidemiology, [10,11] and are
given in Table S1.
Simulation of sulphadoxine-pyrimethamine and drug
resistance. The benefits of SP depend on a combination of
the drug concentration and the frequency of mutations conferring
drug resistance present in the population [6], however the exact
time-course and killing action of SP is not known [12]. Hastings
and Watkins quantify the chances of failing treatment with correct
dosing for dihydrofolate reductase (dhfr) wildtype, 108, doubles,
triples at 0, 0, 0, 50% respectively, while periods of preventive
effect are 52, 12, 12, 2 days [6]. We simulate the action of SP
according to these numbers rounded to the 5 day time steps used
by the simulation model. Although dhps mutations have been
isolated at the sites, they are not considered in this study.
Simulation of clinical episodes. The primary trial outcome
was clinical episodes, defined as detected fever or history of fever
together with parasitaemia, and infants were regarded as not at
risk for the following 21 days [3]. In our simulations, only fevers
presenting for treatment were counted as episodes and the infant
was classified as not at risk for the following 4 five-day periods.
Model 2: Alternative time duration for SP action
The duration of the prophylactic period for SP is not well
established. We vary the duration of SP action from the baseline
model, which has a prophylactic period of 50 days for wildtype
infections [6], to 30 days. This alternative time period was chosen
because drug concentrations of sulfadoxine and pyrimethamine
Figure 1. Simplified processes in the baseline model.
doi:10.1371/journal.pone.0002661.g001
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alone decline log-linearly, but in combination they are synergistic
and an isobologram suggests that there is a sharp drop in SP action
after approximately a month [13]. Observations from field studies
also suggest that the apparent effect of SP lasts for roughly one
month [14–16]. Simulated infections are either sensitive or resistant,
and the resistant infections are unaffected by drug treatment.
Model 3: The timing of fevers produced by a single
infection
In non-immune adults inoculated with P. falciparum as treatment
for neurosyphilis, untreated infections can persist for many
months, during which clinical attacks recur at irregular intervals
[17] (Figure 2). The infections cleared or prevented by IPTi would
therefore have caused repeated fevers, some of which could have
occurred 3 months or more after infection.
The timing of fevers is not well characterized by the baseline
model which tends to produce too little variation, missing both
early and late fevers. We therefore use an alternative, simple
simulation model based on the empirical timing of fevers to
examine whether the temporal pattern of fevers resulting from
individual infections can account for the pattern of trial results for
episodes.
Model 3 is different to the other models in that it is not based on
model 1, other than the algorithms for the number of infections
producing blood-stage parasites in each infant [18]. For each
successful infection, we randomly selected one of the 334
malariatherapy patients’ timing of fevers. Concurrent infections
did not interact and there was no acquired immunity. SP was
assumed to act in the same way as for the baseline model.
Model 4: High parasite densities may not be efficient for
acquiring immunity
Overwhelming parasite densities may not contribute as much to
the accrual of immunity as would the same total number of
parasites experienced in smaller doses over a longer period of time.
Such densities cause fever, and the fever itself may also hinder the
acquisition of immunity, possibly through the loss of T- and B-
cells. We modify the baseline model to reduce the contribution of
parasite density to acquired immunity in the presence of a fever.
In the baseline model (model 1), immunity is modelled as a
function of both the number of distinct infections that the
individual has experienced and his or her cumulative parasite load.
The cumulative exposure to parasites for individual i of age a at
time t, Xy(i,t), is defined as the cumulative sum of daily densities of
asexual parasites/microlitre of blood since birth up to time t. This
can be partitioned into the cumulative sum up to time t-1, the
previous five-day time-step, and the sum of the densities over the
last five days, Y5(i,t),
Xy i,tð Þ~
ðt{1
t{1
Y i,tð Þ dt z Y5 i,tð Þ
For model 4, we include a parameter bf which fixes the
contribution of the current density as Y5(i,t) if a malarial fever is
absent (bf=0 = 1), but may differ from this if a fever is present.
Xy i,tð Þ~
ðt{1
t{1
Y i,tð Þ dt z bf Y5 i,tð Þ
We fitted the new parameter bf to the same datasets used to fit
model 1, simultaneously with the previously defined parameters
[5,10]. These parameters estimates are given in Table S1. To
calculate Xy(i,j,t) to correspond to the published model [7], we
subtract the contribution of infection j to avoid double-counting.
Model 5: Surviving infections are attenuated by SP
allowing extended low-level exposure beneficial to
stimulating immunity
Waning drug concentrations or partial drug resistance may
allow parasites to survive in the presence of SP whilst restricting
their growth [6]. This may allow an extended time for the immune
system to mount a response to the parasite, which could facilitate
the development of immunity to malaria. [19,20]. It is not known
if attenuated infections can lead to enhanced immunity in this way,
although there is some experimental data from mice that suggests
that this may be possible [21]. Low levels of blood stage infection
in humans can induce immunity [22]. We hypothesize that
infections beginning when SP concentrations have decreased to
sub-therapeutic concentrations have reduced densities and longer
durations compared to when there is no SP, and that this enhances
the development of immunity.
We modify the baseline model so that a simulated infection
beginning within a window period after SP treatment has a longer
duration and lower densities. The window period begins as the
prophylactic action ends, and the duration depends on the dhfr
mutations assigned to the simulated infection (wildtype: 10 days;
108/double/triple: 30 days). We simulate parasite densities in the
same way as for the baseline model, except that we reduce all
densities from the infection by a third and extend the duration by a
factor of 3. This value was arbitrarily chosen to represent an upper
limit for plausible values. The potential consequence of model 5 is
to increase the amount of time that an infant has low-level
parasitaemia, which in turn increases the time that the pyrogenic
threshold is high.
Data sources: The field trials
A model of IPTi should capture the approximate time-course of
efficacy of IPTi trials. The most detailed, standardised age-groups
are those provided by a systematic analysis of six IPTi trials using
SP [3]. For practical reasons, we omit studies not included in this
report [23–26]. All six included trials were carefully conducted
and independently monitored [3].
Figure 2. Timing of fevers* resulting from single infections in
334 neurosyphilis patients. *One fever counted per five-day
interval. This data was collected by the United States Public Health
Service in South Carolina and Georgia between 1940 and 1963 and was
provided by Dr W Collins (Centers for Disease Control and Prevention,
Atlanta, GA).
doi:10.1371/journal.pone.0002661.g002
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A critical input for the models is transmission intensity.
Reported seasonal entomological inoculation rates (EIR) and/or
age-prevalence curves were available from three trial sites
(Manhic¸a, Ifakara and Navrongo) [15,27–29], but not for the
remaining three (Tamale, Kumasi and Lambare´ne´) [30–32]. Thus
the formal comparison of models and empirical data was restricted
to simulations from the former three trials, whilst the latter were
used to validate model output against general patterns in the trial
results.
For some age-groups, efficacy estimates for episodes defined
with two different parasite density cut-offs are available: fever plus
parasitaemia of any density, and fever plus high parasite density.
In most cases there is little difference [3,15,27–29]. However, a
discrepancy arises in Navrongo [3,15] for children over one year
of age where the estimated efficacy for high density episodes
($5000/ml) suggests an increase in episodes in the IPTi group
compared to the placebo group which is not apparent for episodes
with parasitaemia of any density. In this case, we use the high
density definition because it is likely to be more specific in a high
transmission area and as age increases [33,34].
Specifying model input values for the trial sites
Transmission intensity, seasonality and ITN use. We
based our model inputs on the published data for seasonality and
transmission intensities (Table 1). In Ifakara, the extensive
coverage of insecticide-treated nets (ITNs) may have
substantially decreased transmission from the reported EIR of 30
per year. Our baseline model does not explicitly include a
component for the impact of ITNs, this is currently being
implemented [35]. However the most relevant consequence for
modelling trials of IPTi would be the reduction in transmission to
the infants. It is likely that ITN use would also decrease onward
transmission, but is not expected to alter the sporozoite load of an
infectious mosquito, nor would a lower sporozoite load be likely to
lead to less severe outcomes in humans [36–38].
For the Ifakara trial, we gauged the effective overall EIR by
comparing observed age-prevalence [39,40] and age-incidence
curves for uncomplicated episodes [39] and malaria hospital
admissions [41] to simulated age curves for a range of annual EIR
values. The best-fitting age patterns were produced by an EIR of
approximately 4. We also considered the effects of decreasing
transmission intensity and reduced seasonality [41]. Decreasing
transmission has been proposed as a possible explanation for the
high protective efficacy estimates observed in the Ifakara trial [42].
For Manhic¸a and Navrongo, we did not adjust the overall EIR for
ITN use. The inputs for the Manhic¸a field site have been
previously characterized for the baseline model [43]. We validated
our input EIR value for Navrongo by comparing the simulated
age-prevalence curve against two sets of survey data [7,44]. In
addition, we restricted the simulations for Ifakara to infants who
Table 1. Study sites and trial characteristics.
Schellenberg
et al[27,28]
Chandramohan
et al[15]
Macete
et al[29]
Kobbe
et al[31]
Mockenhaupt
et al[32]
Grobusch et
al[30]
Study site Ifakara, Tanzania Navrongo, Ghana Manhic¸a,
Mozambique
Kumasi, Ghana Tamale, Ghana Lambare´ne´,
Gabon
Pattern of seasonality1 Perennial Marked seasonality Perennial Perennial Perennial Perennial
Study period 1999–2001 2000–2004 2002–2005 2003–2005 2003–2005 2002–2006
Transmission Intensity (Infectious
bites/adult/year)
29[61] in 1999–2000 418[62] in 2001–02 38 in 2001–02 approx 400 NK (high) Approx 50
ITN coverage 67% 17% 0% 20% ,1% 5%
Untreated net coverage 15% 20% ,1% 85%
Day 14 ACPR* (95% CI) 66% (55,76)[63] 78% (69, 85)[64] 83% (73, 90)[65] { 86%(79,91)[66] 79% (64,90)
{[67]
Trial characteristics
Primary outcome: Protective efficacy
first dose to 12 months[3]
58.8 (40.9, 71.3) 29.3 (17.3, 39.6) 20.1 (2.0, 34.9) 20.9 (8.9, 31.3) 33.3 (20.7, 43.9) 22.0 (225.4,
51.5)
Number of infants enrolled
(placebo/active)
351/350 1242/1243 755/748 535/535 600/600 595/594
Level of randomisation Individual Community Individual Individual Individual Individual
Schedule of IPTi doses (months) 2, 3 and 9 3, 4, 9 and 12 3, 4 and 9 3,9 and 15 3,9 and 15 3,9 and 15
Mean age at doses (months) 2.2, 3.3 and 9.2 3.0, 4.0, 9.5 and 12.6 3.3, 4.4, 9.4 2.8 2.4, 8.1, 14.3 3.1,9.3, 15.3
Coverage 100%, 95%, 84% 95%, 95%, 90%, 91%. 100%,96%,91% 100%,100%,99% 100%,98%,98%
Method of case detection Passive Passive Passive Passive+Active
(monthly)
Passive+Active
(3-monthly)
Passive+Active
(monthly)
First-line treatment SP quinine CQ and SP quinine CQ or SP+AQ
quinine
Artesunate+AQ Artesunate Artesunate
(+AQ)
Rescue treatment
Routine iron supplementation Yes Yes No No No No
*ACPR= adequate parasitological cure rates in clinical cases (6 months–5 years, or ,5 years).
{Children aged 1–10 years.
ITN= insecticide treated net. NK = not know.
1Roca-Feltrer et al, in prep.
{79% infants with triple dhfr and/or dhps mutations at IPTi-3 [31].
doi:10.1371/journal.pone.0002661.t001
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reached 2 months of age between August and April in order to
correspond to the recruitment period.
Treatment of clinical episodes. Only simulated fevers
presenting for treatment were counted as episodes and the infant
was classified as not at risk for the following 4 five-day periods to
correspond to the trial definitions [3]. The proportion of malaria
fevers that presented for treatment in the trials is unknown. We
estimated this proportion by assuming that fevers were treated
with a constant probability. We adjusted this probability until our
simulations of the time to first treated episode matched the
published Kaplan-Meier curves for the placebo groups. The
closest matches were found for Ifakara, Manhic¸a and Navrongo
using 20%, 4% and 7% respectively. The value of 4% in infants in
Manhic¸a was similar to the previous estimate of 5% for children
1–4 years in a vaccine trial [43]. The pattern of the estimates is
plausible because the Ifakara study area was centred around a
town with relatively good access to the health facility whereas the
other trial settings were rural. We assumed that 48% of the severe
episodes presented for treatment in all trials [9].
Clinical episodes presenting for treatment were given SP in
Ifakara and SP with chloroquine (CQ) in Navrongo (Table 1). In
Manhic¸a, the national policy changed from CQ to amodiaquine
(AQ) plus SP during the course of the trial. We simulate CQ and
SP as clearing all infections, sensitivity analyses show that this
assumption is not critical. The rescue treatment in the Ifakara,
Manhic¸a and Navrongo trials was quinine which was given if the
infant was admitted to hospital with malaria, presented within 2
weeks of an IPTi or placebo dose, or presented within 14 days of
receiving SP. We simulate quinine as clearing all infections within
a five-day time-step.
Frequencies of dhfr mutations. Each simulated infection
was assigned a genotype (dhfr wildtype, 108 or double mutations,
or triple mutations). The frequency of dhfr mutations in each trial
site is uncertain. Fourteen day adequate clinical and
parasitological cure rates (ACPR) are available (Table 1), but
they underestimate the true failure rate [12,45]. It is not possible to
determine by how much the rate is underestimated for an
individual site because the 14 day parasitological failure rates have
a low predictive value [45,46]. Estimating dhfr genotype
frequencies from data on the prevalence of mutations in infected
humans is also difficult, because a combination of mutations may
be formed in various ways when there are multiple infections. We
aim to determine only whether the trial results can be reproduced
for a reasonable assumed value of the frequency of dhfr mutations
combined with the baseline model, and so we simulate the trials
over a range of assumed frequencies. The lower bound of this
range was provided by converting the lower confidence interval of
the 14 day failure rates into dhfr genotype frequencies using
simulations of the trials which had reported the 14 day failure
rates. The value producing the best-fitting predictions within this
range was chosen.
Scenarios used for predicting the impact of IPTi outside
of the trial settings
We predicted age-specific protective efficacy and cumulative
protective efficacy up to the age of four years.
We define the cumulative protective efficacy as
1{
ci=pyari
cp

pyarp
 !
where c is the cumulative number of episodes
in the IPTi (i) or placebo (p) groups and pyar are the person-years at
risk.
We also predicted the number of acute episodes, severe episodes
and combined direct and indirect malaria deaths that would be
averted for a period of 20 years following the introduction of IPTi
in a population aged 0 to 90 years. We assumed a reference
scenario with IPTi doses at 3, 4 and 9 months and then changed
the values of different variables one by one to investigate their
effects on the predicted impact (Table 2). The simulations were
based on a population of 200,000 individuals, with an approxi-
mately stationary age-distribution matching that of the demo-
graphic surveillance site in Ifakara, Tanzania, in 1997–99 [47].
Results
Comparison of models with different mechanisms for IPTi
The agreement between the baseline model predictions and
observed trial estimates was generally good (Figure 3 and Table 3).
However, the continued positive protective effects of IPTi
observed in Ifakara between doses and after the last dose were
not fully captured. The Ifakara trial results for the periods between
doses and after the last dose could be matched by reducing the
transmission intensity as found in another study [42], but only if
the intensity was reduced by at least 70% in the second year.
Table 2. Variables that vary between scenarios**.
Variable Description Levels
Intensity of
transmission
Infected bites per adult
per year prior to the
introduction of IPTi{
High transmission: 200
Moderate transmission:
100
Reference: 21
Low transmission: 6
Treatment coverage Proportion of malaria fevers
treated
4%, 30%
Drug resistance Frequency of 3 different
genotypes
100%, 0%, 0%
80%, 10%, 10%
20%, 40%, 40%
0%, 0%, 100%
Prophylactic period Time in days that drug
clears blood-stage infections
for each of the 3 different
genotypes {
0,0,0 days (treatment
only)
50, 10, 0 days
(corresponds to SP)
100, 20, 0 days
IPTi schedule Age at doses 3, 4 and 9 months
Single doses 1.5–24
months*
IPTi coverage Proportion of eligible infants
receiving all 3 IPTi doses
(coverage with first, second
and third dose)
89% (95%,95%,99%)
50% (79%,79%,79%)
100% (100%,100%,100%)
**One variable was varied at a time. In each scenario, the variables not being
evaluated were fixed at the reference levels (indicated in bold).
{The seasonality follows that of Namawala, Tanzania.[68] Each simulation
assumes a recurring pattern of the vectoral capacity.
{The proportion of infections cleared by the genotypes are set at 100%,100%
and 50%.
*We investigated the effect of age at dose by simulating a single IPTi dose at
varying ages.
doi:10.1371/journal.pone.0002661.t002
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We compared the fit of the different models using weighted
sums of squares (Table 3). None of the alternative models
substantially improved agreement over that of the baseline model.
However, models 2 and 4 also produced predictions which fell
within the confidence intervals of the estimates of protective
efficacy obtained in the trials (not shown) and could not be ruled
out as providing an explanation for the effects of IPTi. Altering the
duration of SP action (model 2) improved the fit slightly in the case
of Navrongo and Manhic¸a, but reduced the fit for Ifakara, in
comparison to the baseline model. Overall, however, the
predictions were similar to those of the baseline model which
can most likely be attributed to the similarity of the assumed action
of SP since only the duration was altered. The predictions made by
model 4 (where fevers penalized the acquisition of immunity) did
not substantially differ from those of model 1. The greatest
difference was seen in the results for Ifakara, where the assumption
of benefits to acquired immunity from avoiding fevers increased
the predicted efficacy between doses and after the last dose.
Models 3 and 5 both incorporated processes to lengthen the
duration of SP action beyond the duration of active drug
concentrations. Their results were not consistent with Navrongo
trial estimates, since they failed to capture the lack of effect of IPTi
between doses and after the last dose. However, these models best
predicted the high efficacy estimates observed between doses and
after the last dose in the Ifakara trial.
Model 1 also adequately predicted the impact of IPTi on
hospital admissions (Table 4).
Figure 3. Comparison of trial estimates and baseline model predictions of protective efficacy of IPTi with SP against clinical
episodes, by age group. Open circles = Trial estimate with 95% confidence interval. Filled circles = Baseline model prediction. Protective
efficacy = percentage reduction in incidence of clinical episodes in IPTi group compared to placebo group. The age groups that the morbidity
surveillance refers to are illustrated on the right-hand side. The arrows point to the scheduled ages at IPTi doses.
doi:10.1371/journal.pone.0002661.g003
Table 3. Model fit for acute episodes assessed by weighted
sums of squares.
Description of model Navrongo Manhic¸a Ifakara Total
Model 1 Baseline 0.618 0.046 0.239 0.903
Model 2 30 day SP action 0.557 0.039 0.386 0.982
Model 3 Repeat episodes 1.515 0.534 0.089 2.138
Model 4 Avoiding fevers 0.699 0.043 0.180 0.922
Model 5 Attenuated infections 2.845 0.423 0.128 3.396
We calculated the squared difference between the trial estimate and the
predicted protective efficacy, weighted them by the number of person years at
risk/100 and summed them to give a measure of the goodness-of-fit. A smaller
value indicates a better fit. The three trials with EIR measurements were
formally used to test the models, the remaining three were used only to
validate the model output against general patterns in the trial results.
doi:10.1371/journal.pone.0002661.t003
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We also compared the output of the baseline model with the
three trials not included in the formal comparison. They reported
efficacy estimates in line with the Manhic¸a and Navrongo trials.
Only previously unobserved features were used for further
validation of the baseline model. In the trial in Kumasi [31],
IPTi doses were given at 3, 9 and 15 months of age. Kumasi
villages with higher incidence of malaria in the placebo group
show a linear increase in observed protective efficacy in the
following 6 months [48]. Model 1 did not reproduce this result.
Our simulated protective efficacy showed either no change or a
slight decrease over a wide range of incidence values. The
observed association may be due to different health system
coverage in the different villages [49], or the additional influence
of increased acquired immunity on SP efficacy [48]. Alternatively,
the observation may be due to different specificities of case
definitions in the different villages [48]. The model would be able
to capture the effect of treatment coverage if it is known, but at
present is unable to capture the effect of increased immunity on SP
action or effects of different specificities since non-malaria fevers
are not modelled. Model 1 also did not fully capture the large
negative efficacy observed for severe malarial anaemia in the post-
intervention period in the trial in Tamale [32].
Predicted impact of IPTi using the baseline model
Predicted patterns of protective efficacy by age were similar for
acute malaria episodes, severe episodes and malaria-attributable
mortality using model 1 (Figure 4a), with a small negative efficacy
after the final dose for all outcomes. The slight delay in the peak
protective efficacy for mortality is due to the inclusion of indirect
malaria deaths, which occur as a result of an acute episode in
conjunction with a co-morbidity and occur 30 days after the acute
episode [9]. In contrast, the cumulative protective efficacy varied by
outcome in the settings modelled (Figure 4b), at four years of age, the
greatest effect was on mortality, followed by severe episodes. This is
due partly to different predicted age-distributions of episodes in the
placebo group and partly to age-dependent components in the model
for severe episodes and mortality. The cumulative efficacy did not fall
below zero for this or any of the other scenarios we have simulated.
The predicted number of episodes averted increased steadily
over 20 years from the introduction of an IPTi programme
(Figure 5). The linear increase reflects the negligible impact of IPTi
on transmission and the short-term effects of IPTi in individuals.
The predicted number of clinical episodes averted was greatest for
moderate transmission settings (Figure 5a), but the number of
deaths averted was greatest for higher transmission settings
(Figure 5c). The number of deaths averted was greater for settings
with a lower proportion of fevers treated and for IPTi drugs with a
longer prophylactic period (Figure 5). Higher IPTi coverage and
greater drug efficacy (or lower drug resistance) were also predicted
to avert a greater number of episodes (not shown). The small
predicted negative efficacy following the last dose as shown in
Figure 4 was reduced both in settings where the impact of IPTi
was less, such as with low drug efficacy or a high proportion of
treated fevers, and in settings where there was low transmission
intensity and thus little acquired immunity.
We simulated the number of episodes averted for varying
Expanded Programme on Immunization (EPI) schedules (not
Table 4. Observed and predicted protective efficacy for
severe episodes presenting for treatment.
Observed hospital
admissions with
parasitaemia
Observed all-
cause
admissions
Predicted admissions
due to severe malaria
(model 1)
first dose-12months
Ifakara 58.5 (28.7, 75.8) 29.2 (6.6, 46.2) 48.7
Navrongo 50.2 (22.6, 68.0) 17.7 (20.1, 32.3) 32.9
Manhic¸a 22.5 (216.0, 48.2) 24.6 (7.2, 38.7) 30.0
5 months after last dose
Ifakara 15.3 (265.0, 56.5) 24.9 (247.1, 25.2) 18.5
Navrongo 214.2 (295.9, 33.4) 216.3 (253.0, 11.6) 0.04
Manhic¸a 232.0 (2114, 18.2) 8.1 (225.7, 32.8) 21.7
doi:10.1371/journal.pone.0002661.t004
Figure 4. Predicted protective efficacy and cumulative protective efficacy by age. A. Predicted efficacy by age; B. Predicted cumulative
efficacy by age for the reference scenario (summarized in Table 2) using model 1. IPTi doses were given following an EPI schedule at 3, 4 and 9
months of age. Dotted line = clinical malaria episodes; dashed line = severe episodes; solid line =malaria-attributable mortality.
doi:10.1371/journal.pone.0002661.g004
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shown). Predictions suggested that the spacing of doses was
important, with a greater number of episodes averted for doses at 4,
6, 9 months compared to 4, 5, 9 months. For simplicity, we show the
effect of age at the time of doses by simulating a single dose although
the number of episodes averted with a single dose is lower than with
the three dose schedule. A single SP dose was predicted to have a
beneficial impact for all of the transmission intensites and ages up to
24 months. The age at which the maximum number of acute
episodes and deaths were averted for a single SP dose was
approximately 5 months for both high and moderate transmission
intensities, but there is no obvious peak within the first 24 months for
low transmission intensities (Figure 6). For severe episodes, two peaks
are apparent for the high and moderate transmission intensities.
These reflect a shift between two types of severe malaria in the
model. At younger ages, the majority of severe episodes averted are
caused by an acute episode in conjunction with co-morbidity, and at
older ages, overwhelming parasitaemia. For a single dose at older
ages, the number of episodes averted by a single dose is greater for
moderate transmission intensities. At low transmission intensities, it is
been proposed that doses at later ages would avert the greatest
number of episodes [50], and our predictions are consistent with this.
However, there is greater uncertainty in our predictions for low
transmission intensities due to the effects of heterogeneity [5,10].
Discussion
Trial-specific inputs together with the baseline model repro-
duced the pattern of trial results reasonably well. Although there
was no clear ‘best model’, none of the alternative models
substantially improved agreement. This indicates that known
features of malaria epidemiology together with the duration of SP
action can account for the trial results and the variability
between them. However, other hypotheses involving interactions
between drug concentrations and acquired immunity or fevers
and acquired immunity could not be ruled out as possible
mechanisms.
Figure 5. Predicted number of episodes averted by time since start of IPTi programme.
doi:10.1371/journal.pone.0002661.g005
First column Effect of varying EIR from 6 (dotted line), 21(solid line), 100 (dash-dot line), 200 (dashed line) on A) clinical malaria episodes B) severe episodes, C)
malaria-attributable mortality
Second column Effect of varying health system coverage from 4% fevers treated (solid line) to 30% (dashed line) on D) clinical malaria episodes, E) severe episodes, F)
malaria-attributable mortality
Third column Effect of varying prophylactic period for sensitive infections from treatment effect only (dashed line), 50 days (solid line), 100 days (dotted line) on G)
clinical malaria episodes, H) severe episodes, I) malaria-attributable mortality
Variables not being evaluated were fixed at the reference levels defined in Table 2
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Predictions using the baseline model suggest that IPTi using SP
is effective over a wide range of transmission intensities at reducing
malaria clinical episodes and malaria-attributable mortality in
infants. Small negative protective efficacy values were predicted
for a short time following the prophylactic periods, but these were
outweighed by the cumulative benefits.The predicted short-term
impact of IPTi on an individual’s level of immunity and negligible
effect on transmission intensity produced a steady rate of cases
averted in the community over time from the start of an IPTi
programme. IPTi was predicted to avert a greater number of
episodes where IPTi coverage was higher, the health system
treatment coverage lower, and for drugs which were more
efficacious. A greater number of episodes were also averted with
longer drug prophylactic periods, agreeing with considerations
that the prophylactic period is important for IPTi [51]. The
predicted reductions in mortality were not as large as those
observed with ITN programmes or interruption of transmission.
IPTi has a similar effect on severe episodes as a pre-erythrocytic
vaccine with assumed characteristics [52], but a much lower
impact on uncomplicated episodes. This is likely to be due to the
age-distribution of episodes and the longer-lasting effect of the pre-
erythrocytic vaccine. The predictions also point to when IPTi is
likely to not be useful. The number of cases averted is predicted to
be fewer where IPTi coverage is lower, the health system
treatment coverage is higher, and for short-acting drugs. At very
low transmission intensities the predicted number of cases averted
is few, however the model is likely to be less reliable at low
transmission intensities [5,10] and so it is not easy to determine a
transmission intensity below which IPTi is not useful.
This study offers possible explanations for the very strong
positive protective efficacy observed in the Ifakara trial between
doses and following the last dose. Three models produced
predictions consistent with the observed results (Table 3), two
describing a process for the continued positive benefits of IPTi,
either by enhancing the acquisition of immunity (model 5) or by
clearing infections which may have caused future clinical episodes
(model 3), and model 1 in conjunction with sharply decreasing
transmission. Neither model 3 nor 5 reproduced the results from
the other sites as well as model 1. In the case of model 5, it is not
easy to see why enhancing immunity should work only at low
transmission intensities. However, it is possible that effects
resulting from the timing of episodes (model 3) are only apparent
at low transmission intensities. They may be otherwise obscured
by processes such as interactions between infections or acquired
immunity. However, it is also possible that infections have shorter
durations in infants than in adults [53]. Model 1 was able to
Figure 6. Episodes averted per 1000 population over 20 years by a single dose of IPTi by age at dose A) acute malaria episodes B)
severe episodes C) malaria-attributable mortality. Filled squares EIR = 200; hollow triangles EIR = 21; hollow circles EIR = 6; filled circles EIR = 1.
doi:10.1371/journal.pone.0002661.g006
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reproduce the Ifakara trial results only if the initial EIR of 4
decreased by 70% or more in the second year. This is a substantial
decrease and it is not known whether the transmission intensity did
decrease so markedly over the study period (1999–2001). The
incidence of uncomplicated episodes halved between 1995 and
2000 [41]. Decreasing transmission intensity was shown to be
consistent with the Ifakara results in another modelling study, but
also required a substantial decrease of 22% per month [42].
Although the causes underlying the Ifakara results remain
unknown, it seems reasonable that transmission intensity, either
low or decreasing, is likely to have played a role. The potential
contribution of the high coverage of ITNs to the large impact of
IPTi in Ifakara has been noted elsewhere [54].
The predicted impact on indirect malaria mortality was greater
than that on direct malaria mortality. The predictions for indirect
malaria mortality, and to a lesser extent, severe episodes rely on
age-dependent co-morbidity functions. In a trial setting with access
to good health care, the age-pattern of comorbidity may be quite
different to that implicitly assumed by our models, which were
fitted to other datasets [9]. In this case, the impact of IPTi on
severe malaria and malaria-attributable mortality would be
expected to be lower. Reductions in mortality have not been
observed in the field trials reported to date, but the trials were not
powered for this outcome.
This is the most comprehensive model to date, but still has certain
limitations. The model predictions are unlikely to be reliable for low
transmission intensities due to factors such as micro-heterogeneity
and in-migration [10], and thus it is difficult to determine the range
of transmission intenities where IPTi is not useful.
We were unable to capture the effects of drug levels on parasite
population dynamics by the current within-host model which relies
on empirical averaged parasite densities. A within-host model
which will capture immune development more explicitly is in
preparation, and will include several immune responses, fevers and
antigenic variation. It will also allow a more realistic model of the
action of SP.
The model component for the action of SP was compatible with
our model of malaria epidemiology. It is a simple model derived
from dose-response curves and isobolograms [6]. SP is assumed to
act on the infection, either clearing it or not. This model would be
unable to account for certain observed effects such as density-
dependent cure rates or effects of acquired immunity. A more
refined model would allow the drug concentrations to affect
individual parasites. Such a model has been formulated by Gatton
and colleagues [55]. All SP models to date have been constructed
using data on SP concentrations in adults. There is evidence that
SP is cleared more quickly in children and requires a greater dose
per kilogram to reach the same concentrations [56], but little is
known about infants. Data on the pharmacokinetics of SP in
infants and the impact on infections with dhfr and dhps mutations
are needed [57]. Adverse side-effects of SP are beyond the scope of
this model. Although very rare, these have been reported [31].
The model also does not incoporate the effect of IPTi on levels of
drug resistance, which has been modelled elsewhere [58,59].
We did not include the impact of IPTi on anaemia in our
model. Whilst anaemia is an important consequence of malaria,
the lack of knowledge about the dynamic effects of malaria and
anaemia on one another limits our ability to construct a
satisfactory model. We have previously used a model relating
anaemia to the population prevalence of parasitaemia [60] to
predict the impact of pre-erythrocytic vaccines [52]. However, in
the case of IPTi, the short-term blood-stage effects of the drugs
and use of iron supplementation in some of the trials rendered this
model unsuitable. A model of anaemia may be able to account for
the severe malarial anaemia rebound which was observed in the
trial in Tamale [32].
In conclusion, several models reproduced the trial data
adequately so a single clearly preferred hypothesis for the
secondary effect of IPTi on anti-malarial immunity cannot be
identified. The previously published model adopted as our baseline
model [5], with additional components for the action of SP, can
reproduce the trial results using known features of malaria
epidemiology. We propose that this model is suitable for making
predictions of the impact of IPTi. These predictions suggest that
IPTi would have a beneficial impact across a wide range of
settings. These analyses contribute to a growing database of the
likely effectiveness of different malaria control strategies generated
using this common simulation platform [10].
Supporting Information
Table S1 Parameter estimates for the models
Found at: doi:10.1371/journal.pone.0002661.s001 (0.15 MB
DOC)
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